Eyevensys secures $30 mln Series B
Eyevensys, a Paris-based developer of non-viral gene therapies for retinal and other ophthalmic diseases, has raised $30 million in Series B financing.
8 January 2020•4 mins read
Eyevensys, a Paris-based developer of non-viral gene therapies for retinal and other ophthalmic diseases, has raised $30 million in Series B financing.
First In’s new partner brings CIA insights to defense tech
9 November 2026 · 7 mins read
Oman’s Phaze Ventures gathers $40m toward $75m AI fund platform
6 November 2026 · 5 mins read
Radical called the AI boom early. Now it’s doubling down
5 November 2026 · 4 mins read
AI agents drive new cybersecurity investment strategies
4 November 2026 · 10 mins read
LPs press emerging VCs on quality of their networks
3 November 2026 · 3 mins read
Download the November/December 2026 issue of Venture Capital Journal
2 November 2026 · 1 min read
Bites raises $40m Series A round to expand frontline worker learning platform
29 October 2026 · 7 mins read
